Sector News

Pfizer bags CMV vaccine with Redvax buy

January 5, 2015
Life sciences
Pfizer has acquired a controlling interest in Redvax, a spin-off from Switzerland’s Redbiotec, giving it access to a preclinical human cytomegalovirus vaccine candidate.
 
The transaction, the financial details for which have not been disclosed, includes intellectual property and a technology platform related to a second, undisclosed vaccine programme. CMV is a herpes virus and one out of every five children born with infection may experience hearing loss and severe neurologic disorders.
 
Pfizer noted that more children have disabilities due to congenital CMV than “other well-known infections and syndromes”, including Down syndrome, fetal alcohol syndrome, spina bifida and paediatric HIV/AIDS. It also cited the Institute of Medicine’s ranking of the development of a CMV vaccine as a highest priority; the estimated costs associated with the disease for the US healthcare system is at least $1.86 billion annually, more than $300,000 per child.
 
Kathrin Jansen, head of vaccine research and early development at Pfizer, said that with the acquisition of Redvax, “we will seek to develop a vaccine to prevent a difficult disease that can have a devastating and lifelong impact on young children.”
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach